Skip links

Handful of new children’s meds on the horizon. But will they be accessible to children in LMICs?

By Access to Medicine Foundation

New analysis: Just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in paediatric treatment options.

For the original article, please click here.